Neoadjuvant chemotherapy modulates T cell responses in high-grade serous ovarian cancer metastases

ABSTRACT: Our data suggest that neoadjuvant chemotherapy enhances anti-cancer responses of T cells in peritoneal metastases of patients with high-grade serous ovarian cancer but does not decrease levels of immune checkpoint molecules, providing a rationale for sequential chemo-immunotherapy. tRNA was isolated from 35 omental tissue samples of HGSOC metastases either pre or post NACT treatment. RNASeq was performed on poly-A selected mRNA fragments, 100 b.p paired end, and strand specific, on average 40 million reads per sample.

ORGANISM(S): Homo sapiens

SUBMITTER: Oliver Pearce 

PROVIDER: E-GEOD-71340 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress